Study on Combination of Sonodynamic therapy and Molecularly targeting

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K01342
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical systems
• Research Institution: Yokohama College of Pharmacy
• Principal Investigator: Kuwahara Hiroyuki 横浜薬科大学, 薬学部, 准教授 (10598642)
• Co-Investigator(Kenkyū-buntansha): 岩瀬 由未子 横浜薬科大学, 薬学部, 講師 (00521882) ; 梅村 晋一郎 東北大学, 医工学研究科, 教授 (20402787) ; 弓田 長彦 横浜薬科大学, 薬学部, 教授 (40191481)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 超音波 / 音響化学 / 分子標的薬 / CD20抗原

Outline of Final Research Achievements

In this study, the sonodynamically induced antitumor effect of Rituximab (RIT) was investigated in CD20-positive human Burkitt's lymphoma-derived cell line, Raji cells. Apoptosis was examined after the combination of SDT and RIT in HL-60 cells. Apoptosis was analyzed by cell morphology and caspase-3 activity. The cell damage induced by sonication was enhanced by two-fold in the presence of RIT. Histidine significantly inhibited this enhancement. This inhibitory effect suggests that the sonodynamically induced antitumor effect was mediated by sonodynamically generated reactive oxygen species. These results suggest that PHF is a potential sonosensitizer for sonodynamic treatment of solid tumors.

Free Research Field

臨床薬剤学